{ "meta": { "asOf": "2026-08-05", "dataset": "evidence", "generatedAt": "2026-08-05T00:00:00.000Z", "publishingCaveat": "Research and educational data only. Not medical advice, a treatment recommendation, or proof of efficacy. Verify records against primary sources before reuse. Claims reflect the site's evidence grading and editorial interpretation. Citation-audited is not the same as expert-reviewed, and a claim must be read with its limitations and linked evidence.", "recordCount": 28, "reviewState": { "citation-audited": 28 }, "schemaVersion": "1.0.0" }, "records": [ { "directness": "human-mechanism", "evidence": [ { "note": "Demonstrates common but non-universal, treatment-sensitive BLyS dysregulation and imperfect within-person activity tracking.", "relation": "supports", "sourceId": "stohl-2003-blys-longitudinal" }, { "note": "Supports a longitudinal population-level relationship between plasma BLyS and later disease activity.", "relation": "supports", "sourceId": "petri-2008-blys-activity" }, { "note": "Clinical benefit from ligand inhibition supports pathway relevance but cannot validate circulating BAFF as an individual biomarker.", "relation": "qualifies", "sourceId": "navarra-2011-bliss-52" } ], "evidenceStatus": "observational-association", "exportReviewState": "citation-audited", "hub": "b-cell-baff", "id": "baff-expression-heterogeneous", "lastVerified": "2026-07-10", "limitations": [ "BAFF exists in multiple forms and compartments not captured by a single plasma measurement", "Medication, inflammation, B-cell abundance, receptor binding, and clearance can alter measured concentrations", "Population associations do not establish individual prediction or causal mediation" ], "plainLanguage": "BAFF helps B cells survive, and abnormal BAFF measures occur in many people with lupus. Levels vary between people and over time, so a blood BAFF result is not a stand-alone measure of an individual's disease activity.", "relatedClaimIds": [ "baff-inhibition-sle-composite", "baff-not-bcell-elimination", "ifn-blood-signature-subgroup" ], "reviewState": "citation-audited", "studyDesigns": [ "prospective-cohort" ], "technicalText": "A longitudinal SLE cohort found persistently or intermittently elevated serum BLyS in 50% and elevated blood BLyS mRNA in 61%, with corticosteroid-sensitive variation. A larger cohort linked prior or rising plasma BLyS with subsequent activity at the population level, while the earlier study found within-person serum changes did not track activity changes.", "title": "Circulating BAFF/BLyS dysregulation is common but heterogeneous in SLE" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Primary phase 3 source for randomized SRI response and safety results.", "relation": "supports", "sourceId": "navarra-2011-bliss-52" }, { "note": "Defines the current U.S. indication and safety boundaries; it does not imply universal response.", "relation": "defines", "sourceId": "fda-2025-belimumab-label" }, { "note": "Heterogeneous BAFF biology cautions against inferring that the pathway is equally dominant in all SLE.", "relation": "qualifies", "sourceId": "stohl-2003-blys-longitudinal" } ], "evidenceStatus": "supported-clinical-evidence", "exportReviewState": "citation-audited", "hub": "b-cell-baff", "id": "baff-inhibition-sle-composite", "lastVerified": "2026-07-10", "limitations": [ "SRI response is a composite improvement outcome, not remission or cure", "The trial selected seropositive adults with active disease and does not represent every SLE phenotype", "Belimumab was tested as add-on therapy rather than against all modern alternatives" ], "plainLanguage": "In BLISS-52, adding belimumab to standard therapy increased the proportion meeting the SRI composite at one year. The result is an average trial effect, not proof that every person's disease is BAFF-driven.", "relatedClaimIds": [ "baff-expression-heterogeneous", "baff-ln-renal-response", "baff-not-bcell-elimination" ], "reviewState": "citation-audited", "studyDesigns": [ "randomized-controlled-trial", "guideline-or-regulatory" ], "technicalText": "In BLISS-52, week-52 SRI response was 51% with belimumab 1 mg/kg, 58% with 10 mg/kg, and 44% with placebo, all added to standard therapy. The study supports BAFF as a clinically actionable target in its selected population while leaving substantial nonresponse in each active-treatment arm.", "title": "BAFF inhibition improved a composite response outcome in active seropositive SLE" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Primary randomized source for the 104-week renal response results.", "relation": "supports", "sourceId": "furie-2020-bliss-ln" }, { "note": "Current U.S. indication includes active lupus nephritis receiving standard therapy.", "relation": "defines", "sourceId": "fda-2025-belimumab-label" }, { "note": "Places BAFF inhibition within organ-specific, combination treatment and monitoring rather than as a stand-alone cure.", "relation": "qualifies", "sourceId": "kdigo-2024-lupus-nephritis" } ], "evidenceStatus": "supported-clinical-evidence", "exportReviewState": "citation-audited", "hub": "b-cell-baff", "id": "baff-ln-renal-response", "lastVerified": "2026-07-10", "limitations": [ "Both groups received standard induction and maintenance therapy", "Protocol-defined renal response does not establish histologic quiescence or lifelong kidney preservation", "Individual benefit and risk depend on nephritis class, kidney function, comorbidity, prior therapy, and other clinical context" ], "plainLanguage": "In a two-year kidney trial, more participants receiving belimumab plus standard therapy met the study's kidney-response definitions than participants receiving standard therapy alone. A response definition is not the same as kidney cure.", "relatedClaimIds": [ "baff-inhibition-sle-composite", "care-organ-context" ], "reviewState": "citation-audited", "studyDesigns": [ "randomized-controlled-trial", "guideline-or-regulatory" ], "technicalText": "BLISS-LN randomized 448 adults with biopsy-proven active lupus nephritis. At week 104, primary efficacy renal response was 43% with belimumab plus standard therapy versus 32% with placebo plus standard therapy; complete renal response was 30% versus 20%.", "title": "Belimumab added to standard therapy improved protocol-defined renal responses in active lupus nephritis" }, { "directness": "human-mechanism", "evidence": [ { "note": "Primary regulatory description of belimumab's soluble-BLyS binding mechanism.", "relation": "defines", "sourceId": "fda-2025-belimumab-label" }, { "note": "Clinical trial tests BAFF inhibition, not a B-cell-depleting product.", "relation": "supports", "sourceId": "navarra-2011-bliss-52" }, { "note": "CAR-T directly targets CD19-positive cells after lymphodepletion, contradicting mechanistic equivalence with soluble-ligand inhibition.", "relation": "contradicts", "sourceId": "mackensen-2022-car-t-sle" } ], "evidenceStatus": "human-mechanistic-evidence", "exportReviewState": "citation-audited", "hub": "b-cell-baff", "id": "baff-not-bcell-elimination", "lastVerified": "2026-07-10", "limitations": [ "All these interventions can indirectly change overlapping B-cell subsets and biomarkers", "Mechanistic distinction does not by itself rank efficacy or safety", "Cross-trial comparisons remain confounded by population, background therapy, outcome, and follow-up differences" ], "plainLanguage": "Belimumab blocks soluble BAFF/BLyS, a B-cell survival signal. That differs biologically and clinically from antibody-based B-cell depletion or CAR-T, even though all can affect the B-cell system.", "relatedClaimIds": [ "baff-expression-heterogeneous", "baff-inhibition-sle-composite", "cart-no-rituximab-superiority" ], "reviewState": "citation-audited", "studyDesigns": [ "guideline-or-regulatory", "randomized-controlled-trial", "case-series" ], "technicalText": "The belimumab label describes binding to soluble BLyS and inhibition of BLyS binding to B-cell receptors. This modulates survival and differentiation; it should not be represented as direct pan-B-cell elimination, and outcomes cannot be transferred from belimumab to CD20 depletion or CD19 CAR-T.", "title": "BAFF inhibition is not equivalent to eliminating all B cells" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Recommends minimizing glucocorticoid exposure and earlier steroid-sparing treatment.", "relation": "supports", "sourceId": "acr-2025-sle-guideline" }, { "note": "Provides an independent treat-to-target and tapering framework.", "relation": "supports", "sourceId": "eular-2023-sle-recommendations" } ], "evidenceStatus": "established-care", "exportReviewState": "citation-audited", "hub": "cross-cutting", "id": "care-glucocorticoid-minimization", "lastVerified": "2026-07-10", "limitations": [ "Tapering must reflect disease severity and organ risk", "Abrupt discontinuation can be dangerous" ], "plainLanguage": "Steroids can be essential for rapid control, but current guidelines emphasize reducing ongoing exposure because cumulative treatment can cause substantial harm.", "relatedClaimIds": [ "care-hcq-foundational", "care-organ-context" ], "reviewState": "citation-audited", "studyDesigns": [ "guideline-or-regulatory" ], "technicalText": "ACR and EULAR recommendations prioritize the lowest feasible glucocorticoid exposure, with earlier use of steroid-sparing conventional or biologic therapy when needed to control disease.", "title": "Current treatment strategies seek to minimize long-term glucocorticoid exposure" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Current U.S. guideline recommendation and implementation context.", "relation": "supports", "sourceId": "acr-2025-sle-guideline" }, { "note": "Independent international recommendations support broad antimalarial use.", "relation": "supports", "sourceId": "eular-2023-sle-recommendations" } ], "evidenceStatus": "established-care", "exportReviewState": "citation-audited", "hub": "cross-cutting", "id": "care-hcq-foundational", "lastVerified": "2026-07-10", "limitations": [ "A population-level recommendation is not an individual prescription", "Dose and retinal screening require clinician oversight" ], "plainLanguage": "Current major guidelines recommend hydroxychloroquine broadly in lupus, while dose, contraindications, interactions, and eye monitoring require individualized clinical care.", "relatedClaimIds": [ "care-glucocorticoid-minimization" ], "reviewState": "citation-audited", "studyDesigns": [ "guideline-or-regulatory" ], "technicalText": "The 2025 ACR guideline recommends routine hydroxychloroquine treatment unless contraindicated; EULAR likewise places antimalarial therapy at the foundation of SLE management.", "title": "Hydroxychloroquine is foundational therapy for most people with SLE when not contraindicated" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Primary U.S. label for indication, population, administration, warnings, and adverse reactions.", "relation": "supports", "sourceId": "fda-2025-obinutuzumab-ln-label" } ], "evidenceStatus": "established-care", "exportReviewState": "citation-audited", "hub": "cross-cutting", "id": "care-obinutuzumab-us-ln", "lastVerified": "2026-07-10", "limitations": [ "U.S.-specific regulatory status", "The label contains boxed warnings and important infection and monitoring considerations" ], "plainLanguage": "In the United States, obinutuzumab has a lupus-nephritis indication for adults receiving standard therapy. Approval does not mean it is appropriate for every person or approved the same way everywhere.", "relatedClaimIds": [ "care-organ-context" ], "reviewState": "citation-audited", "studyDesigns": [ "guideline-or-regulatory" ], "technicalText": "The October 2025 U.S. prescribing information added active lupus nephritis in adults receiving standard therapy to the labeled indications for obinutuzumab.", "title": "The FDA label includes obinutuzumab for adults with active lupus nephritis receiving standard therapy" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Organ-specific recommendations and shared decision-making framework.", "relation": "supports", "sourceId": "acr-2025-sle-guideline" }, { "note": "Kidney-specific treatment and monitoring context.", "relation": "supports", "sourceId": "kdigo-2024-lupus-nephritis" } ], "evidenceStatus": "established-care", "exportReviewState": "citation-audited", "hub": "cross-cutting", "id": "care-organ-context", "lastVerified": "2026-07-10", "limitations": [ "Guidelines cannot encode every clinical circumstance", "Jurisdiction, access, age, pregnancy, and comorbidity evidence may differ" ], "plainLanguage": "There is no single ranked treatment list for everyone with lupus. Kidney disease, pregnancy plans, infections, prior responses, access, and individual goals can change the safest option.", "relatedClaimIds": [ "care-glucocorticoid-minimization", "care-obinutuzumab-us-ln" ], "reviewState": "citation-audited", "studyDesigns": [ "guideline-or-regulatory" ], "technicalText": "Contemporary systemic and kidney guidelines use organ- and context-specific treatment pathways and emphasize shared decision-making rather than diagnosis-wide ranking.", "title": "Lupus treatment depends on organ involvement, severity, reproductive context, comorbidities, and patient priorities" }, { "directness": "inference", "evidence": [ { "note": "Registered phase 1/2 lupus-nephritis study.", "relation": "supports", "sourceId": "nct05938725-kysa-1" }, { "note": "Registered phase 1/2 severe refractory SLE study.", "relation": "supports", "sourceId": "nct05798117-ytb323" }, { "note": "Registered phase 2 active SLE study.", "relation": "supports", "sourceId": "nct07015983-breakfree-sle" } ], "evidenceStatus": "emerging-preliminary", "exportReviewState": "citation-audited", "hub": "car-t", "id": "cart-controlled-evidence-pending", "lastVerified": "2026-07-10", "limitations": [ "Registry statuses change", "Planned outcomes are not observed outcomes", "Open-label programs remain vulnerable to selection and measurement bias" ], "plainLanguage": "Several formal studies are now following people with severe lupus who receive different CD19 CAR-T products. A trial listing tells us what researchers plan to measure; it does not show that the treatment works.", "relatedClaimIds": [ "cart-early-remission-refractory-sle" ], "reviewState": "citation-audited", "studyDesigns": [ "trial-registry" ], "technicalText": "Phase 1/2 and phase 2 programs are evaluating safety, cellular kinetics, DORIS remission, and renal response in severe or treatment-refractory SLE. Registry status and enrollment are operational metadata and should be refreshed independently of scientific claims.", "title": "Prospective trials are testing CAR-T in SLE, but registry entries are not results" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Five-person compassionate-use SLE series reported drug-free remission during reported follow-up.", "relation": "supports", "sourceId": "mackensen-2022-car-t-sle" }, { "note": "All eight SLE participants in the 15-person autoimmune series met DORIS remission in the reported follow-up.", "relation": "supports", "sourceId": "muller-2024-car-t-autoimmune" }, { "note": "Defines what DORIS remission does and does not mean.", "relation": "defines", "sourceId": "doris-2021-definition" } ], "evidenceStatus": "emerging-preliminary", "exportReviewState": "citation-audited", "hub": "car-t", "id": "cart-early-remission-refractory-sle", "lastVerified": "2026-07-10", "limitations": [ "No randomized comparator", "Small, highly selected cohorts", "CAR-T was delivered with lymphodepleting chemotherapy", "Reported remission does not establish cure or lifelong durability" ], "plainLanguage": "In small groups of people with very severe lupus that had not responded to multiple treatments, many entered remission after CD19 CAR-T. This is encouraging, but it is not yet a fair comparison with standard treatment.", "relatedClaimIds": [ "cart-safety-bounded", "cart-reconstitution-naive-b-cells", "cart-no-rituximab-superiority" ], "reviewState": "citation-audited", "studyDesigns": [ "case-series" ], "technicalText": "A five-person compassionate-use series and a later case series that included eight participants with SLE reported marked clinical improvement and DORIS remission after autologous CD19 CAR-T plus lymphodepletion. These uncontrolled observations provide a rationale for prospective trials, not an estimate of comparative efficacy.", "title": "Small early cohorts report remission after CD19 CAR-T" }, { "directness": "inference", "evidence": [ { "note": "The report had no rituximab control arm.", "relation": "qualifies", "sourceId": "mackensen-2022-car-t-sle" }, { "note": "The follow-up series had no comparative treatment arm.", "relation": "qualifies", "sourceId": "muller-2024-car-t-autoimmune" }, { "note": "The phase 2 study is open-label rather than a rituximab comparison.", "relation": "qualifies", "sourceId": "nct07015983-breakfree-sle" } ], "evidenceStatus": "contradicted", "exportReviewState": "citation-audited", "hub": "car-t", "id": "cart-no-rituximab-superiority", "lastVerified": "2026-07-10", "limitations": [ "This is a boundary on interpretation, not evidence that the two treatments are equivalent" ], "plainLanguage": "CAR-T and rituximab should not be ranked from the available studies. The CAR-T reports involve selected patients and do not directly compare the treatments.", "relatedClaimIds": [ "cart-early-remission-refractory-sle" ], "reviewState": "citation-audited", "studyDesigns": [ "case-series", "trial-registry" ], "technicalText": "The current source set contains no randomized or suitably controlled head-to-head SLE study of CD19 CAR-T versus rituximab. Mechanistic arguments about depth of B-cell depletion cannot substitute for comparative clinical evidence.", "title": "CAR-T has not been shown to outperform rituximab in SLE" }, { "directness": "human-mechanism", "evidence": [ { "note": "Reported B-cell depletion followed by reconstitution with naive phenotypes in the small SLE cohort.", "relation": "supports", "sourceId": "mackensen-2022-car-t-sle" }, { "note": "Follow-up supports a reconstitution pattern but remains too short and small to establish permanent tolerance.", "relation": "qualifies", "sourceId": "muller-2024-car-t-autoimmune" } ], "evidenceStatus": "human-mechanistic-evidence", "exportReviewState": "citation-audited", "hub": "car-t", "id": "cart-reconstitution-naive-b-cells", "lastVerified": "2026-07-10", "limitations": [ "Peripheral-blood phenotype may not capture tissue-resident cells", "Naive phenotype is not equivalent to absence of autoreactivity", "Long-term relapse mechanisms are not established" ], "plainLanguage": "In early studies, B cells returned after a period of depletion and were mostly immature or naive cells. Researchers call this an immune-reset hypothesis; it has not been shown to permanently restore tolerance.", "relatedClaimIds": [ "cart-early-remission-refractory-sle", "ebv-cart-mechanism-unproven" ], "reviewState": "citation-audited", "studyDesigns": [ "case-series", "human-mechanistic" ], "technicalText": "The early SLE reports describe B-cell aplasia followed by reconstitution dominated by naive B-cell phenotypes. This is consistent with, but does not prove, a durable reset of autoreactive memory or immune tolerance.", "title": "B-cell return after CAR-T may differ from the pretreatment state" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Primary safety observations from 15 autoimmune-disease participants.", "relation": "supports", "sourceId": "muller-2024-car-t-autoimmune" }, { "note": "Ongoing follow-up specifically measures adverse events for up to two years.", "relation": "qualifies", "sourceId": "nct05938725-kysa-1" } ], "evidenceStatus": "emerging-preliminary", "exportReviewState": "citation-audited", "hub": "car-t", "id": "cart-safety-bounded", "lastVerified": "2026-07-10", "limitations": [ "Safety results pool three autoimmune diseases", "Small cohorts cannot characterize rare or late events", "Cross-study comparisons with cancer CAR-T are confounded by population, product, and treatment differences" ], "plainLanguage": "The first published lupus cohorts mostly reported low-grade cytokine release syndrome, but CAR-T also involves chemotherapy, a period of low B cells, and infection risk. Small studies cannot reveal rare harms.", "relatedClaimIds": [ "cart-early-remission-refractory-sle" ], "reviewState": "citation-audited", "studyDesigns": [ "case-series" ], "technicalText": "In the 15-person autoimmune case series, ten participants had grade 1 CRS; one each had grade 2 CRS, grade 1 ICANS, and pneumonia requiring hospitalization. The sample is inadequate for stable incidence estimates or comparison with oncology populations.", "title": "Early safety experience is limited and cannot exclude uncommon serious harms" }, { "directness": "inference", "evidence": [ { "note": "Identifies a plausible CD19-positive EBV reservoir.", "relation": "supports", "sourceId": "younis-2025-ebv-b-cells" }, { "note": "Reports remission but does not test EBV clearance as a mediator.", "relation": "qualifies", "sourceId": "muller-2024-car-t-autoimmune" } ], "evidenceStatus": "site-hypothesis", "exportReviewState": "citation-audited", "hub": "ebv", "id": "ebv-cart-mechanism-unproven", "lastVerified": "2026-07-10", "limitations": [ "Connection is an explicit site inference", "CAR-T affects a broad B-cell compartment and downstream immune networks" ], "plainLanguage": "CAR-T removes many CD19-positive B cells, which can include cells carrying EBV. The studies do not show that removing EBV-infected cells is why lupus improved.", "relatedClaimIds": [ "cart-reconstitution-naive-b-cells", "ebv-reprograms-b-cells" ], "reviewState": "citation-audited", "studyDesigns": [ "human-mechanistic", "case-series" ], "technicalText": "The EBV-positive B-cell model and CAR-T remission observations are biologically connectable, but no cited study measures EBV-positive clone removal as the mediator of clinical remission or compares outcomes by EBV burden.", "title": "CAR-T remission cannot currently be attributed to elimination of EBV-positive B cells" }, { "directness": "human-mechanism", "evidence": [ { "note": "Found significant associations for some EBV antibody markers and explicitly reported marker-specific null findings and possible publication bias.", "relation": "supports", "sourceId": "hanlon-2014-ebv-meta" } ], "evidenceStatus": "observational-association", "exportReviewState": "citation-audited", "hub": "ebv", "id": "ebv-epidemiologic-association", "lastVerified": "2026-07-10", "limitations": [ "EBV exposure is common in the general population", "Case-control serology cannot establish that EBV preceded lupus", "Immunosuppression and altered immune control in SLE can affect EBV measurements" ], "plainLanguage": "People with lupus are more likely than controls to have some signs of previous or active EBV exposure. Because EBV is already very common and most studies look backward in time, this does not prove that the virus caused an individual's lupus.", "relatedClaimIds": [ "ebv-reprograms-b-cells", "ebv-not-sole-cause" ], "reviewState": "citation-audited", "studyDesigns": [ "systematic-review", "case-control" ], "technicalText": "A meta-analysis of case-control studies found higher anti-VCA IgG seroprevalence in SLE but not a statistically significant difference for anti-EBNA1 IgG; other markers also varied. The evidence supports an association while leaving temporal order, residual confounding, and publication bias unresolved.", "title": "EBV markers are associated with SLE, but the association is marker-specific" }, { "directness": "inference", "evidence": [ { "note": "Reported publication bias concerns, methodological limitations, and a null association for anti-EBNA1 IgG.", "relation": "qualifies", "sourceId": "hanlon-2014-ebv-meta" }, { "note": "Provides a mechanism but is not a prospective causal or prevention study.", "relation": "qualifies", "sourceId": "younis-2025-ebv-b-cells" } ], "evidenceStatus": "contradicted", "exportReviewState": "citation-audited", "hub": "ebv", "id": "ebv-not-sole-cause", "lastVerified": "2026-07-10", "limitations": [ "Absence of proof of a universal cause does not rule out an important causal contribution in a subset" ], "plainLanguage": "EBV may contribute to lupus in some people, but it is not accurate to say that the virus explains all—or most—cases from the evidence available here.", "relatedClaimIds": [ "ebv-epidemiologic-association", "ebv-reprograms-b-cells" ], "reviewState": "citation-audited", "studyDesigns": [ "systematic-review", "human-mechanistic" ], "technicalText": "The evidence base supports epidemiologic association and a plausible human mechanism. It does not establish necessity, sufficiency, attributable fraction, or a single primary initiating mechanism across genetically and clinically heterogeneous SLE.", "title": "Current evidence does not establish EBV as a necessary or sufficient cause of SLE" }, { "directness": "inference", "evidence": [ { "note": "Supplies biological rationale for prevention research, not prevention efficacy.", "relation": "supports", "sourceId": "younis-2025-ebv-b-cells" }, { "note": "Association is insufficient to estimate a vaccine prevention effect.", "relation": "qualifies", "sourceId": "hanlon-2014-ebv-meta" } ], "evidenceStatus": "site-hypothesis", "exportReviewState": "citation-audited", "hub": "ebv", "id": "ebv-prevention-untested", "lastVerified": "2026-07-10", "limitations": [ "No SLE prevention effect has been measured", "A useful prevention study would require long follow-up and careful high-risk cohort design" ], "plainLanguage": "An EBV vaccine is an important research idea, but no lupus prevention trial has shown that vaccination lowers lupus risk.", "relatedClaimIds": [ "ebv-reprograms-b-cells" ], "reviewState": "citation-audited", "studyDesigns": [ "systematic-review", "human-mechanistic" ], "technicalText": "The mechanistic and epidemiologic evidence creates a testable prevention hypothesis. It does not justify recommending EBV vaccination as an SLE-prevention intervention outside applicable vaccine research or future approved indications.", "title": "Preventing EBV has not been shown to prevent lupus" }, { "directness": "human-mechanism", "evidence": [ { "note": "Primary human single-cell and functional study of EBV-positive B cells in SLE.", "relation": "supports", "sourceId": "younis-2025-ebv-b-cells" }, { "note": "Earlier epidemiology supports association but not necessity or sufficiency.", "relation": "qualifies", "sourceId": "hanlon-2014-ebv-meta" } ], "evidenceStatus": "human-mechanistic-evidence", "exportReviewState": "citation-audited", "hub": "ebv", "id": "ebv-reprograms-b-cells", "lastVerified": "2026-07-10", "limitations": [ "One mechanistic study requires independent replication", "Cross-sectional detection cannot establish when the B-cell program emerged", "The population fraction of SLE attributable to this mechanism is unknown" ], "plainLanguage": "Researchers found a small population of EBV-infected B cells in lupus with gene activity that could help present self-antigens and activate other immune cells. It is a plausible mechanism, not yet a complete causal chain.", "relatedClaimIds": [ "ebv-epidemiologic-association", "ebv-not-sole-cause", "ebv-prevention-untested" ], "reviewState": "citation-audited", "studyDesigns": [ "human-mechanistic" ], "technicalText": "Single-cell and functional analyses identified transcriptionally distinct EBV-positive B cells in SLE and implicated EBNA2/RBPJ-linked antigen-presentation programs and activation of autoreactive CD4 T cells. This materially strengthens a mechanistic model but does not show that the program initiates most SLE.", "title": "A 2025 human study identified an EBV-positive antigen-presenting B-cell program in SLE" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Positive prespecified BICLA primary endpoint in TULIP-2.", "relation": "supports", "sourceId": "morand-2020-tulip-2" }, { "note": "TULIP-1 did not meet its prespecified SRI-4 primary endpoint and bounds any claim of uniform phase 3 efficacy.", "relation": "contradicts", "sourceId": "furie-2019-tulip-1" } ], "evidenceStatus": "supported-clinical-evidence", "exportReviewState": "citation-audited", "hub": "interferon", "id": "ifn-blockade-mixed-phase3", "lastVerified": "2026-07-10", "limitations": [ "BICLA and SRI-4 are different composite outcomes and cannot be treated as interchangeable", "Both studies tested add-on therapy in selected trial populations over one year", "Neither individual trial determines effectiveness for every organ domain or patient subgroup" ], "plainLanguage": "One major anifrolumab trial met its main composite response endpoint; a closely related trial did not meet its different main endpoint. Together they support the pathway as clinically relevant while warning against describing the evidence as uniformly positive.", "relatedClaimIds": [ "ifn-blood-signature-subgroup", "ifn-signature-not-binary-selector", "ifn-label-bounded" ], "reviewState": "citation-audited", "studyDesigns": [ "randomized-controlled-trial" ], "technicalText": "TULIP-2 reported week-52 BICLA response in 47.8% with anifrolumab versus 31.5% with placebo. TULIP-1 did not meet its week-52 SRI-4 primary endpoint: 36% versus 40%, respectively. Endpoint choice and restricted-medication rules contributed to interpretive complexity but do not erase the prespecified null result.", "title": "Type I interferon receptor blockade produced discordant primary-endpoint results across two phase 3 SLE trials" }, { "directness": "human-mechanism", "evidence": [ { "note": "Primary human discovery study of the peripheral-blood interferon-inducible signature.", "relation": "supports", "sourceId": "baechler-2003-ifn-signature" }, { "note": "Prespecified IFN-high and IFN-low strata show that active SLE is not uniformly signature-high.", "relation": "qualifies", "sourceId": "morand-2020-tulip-2" } ], "evidenceStatus": "human-mechanistic-evidence", "exportReviewState": "citation-audited", "hub": "interferon", "id": "ifn-blood-signature-subgroup", "lastVerified": "2026-07-10", "limitations": [ "Whole-blood expression can differ from pathway activity in kidney, skin, brain, and lymphoid tissue", "Assay genes, cut points, sample handling, medication, infection, and ancestry can alter classification", "The signature is an indirect pathway readout and is not specific to SLE" ], "plainLanguage": "Many—but not all—people with active lupus have a high blood-gene pattern associated with type I interferon activity. This is a pathway signal, not a complete explanation of lupus or a stand-alone diagnostic test.", "relatedClaimIds": [ "ifn-blockade-mixed-phase3", "ifn-signature-not-binary-selector", "baff-expression-heterogeneous" ], "reviewState": "citation-audited", "studyDesigns": [ "human-mechanistic", "randomized-controlled-trial" ], "technicalText": "Peripheral-blood transcriptomic studies identified an interferon-inducible gene-expression cluster in a subset of SLE samples. In the pooled phase 3 anifrolumab program, most enrolled participants were IFN-signature-high, while a distinct IFN-signature-low group remained, demonstrating molecular heterogeneity within clinically active SLE.", "title": "An interferon-inducible blood gene-expression pattern is present in a substantial SLE subgroup" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Current primary U.S. source for indication, limitations of use, and warnings.", "relation": "defines", "sourceId": "fda-2026-anifrolumab-label" }, { "note": "Trial report documents the higher herpes-zoster frequency and studied population underlying part of the label evidence.", "relation": "supports", "sourceId": "morand-2020-tulip-2" } ], "evidenceStatus": "established-care", "exportReviewState": "citation-audited", "hub": "interferon", "id": "ifn-label-bounded", "lastVerified": "2026-07-10", "limitations": [ "U.S.-specific status and wording can change", "Regulatory eligibility is not an individual recommendation", "The label should be consulted directly for full contraindications, warnings, administration, and monitoring information" ], "plainLanguage": "Anifrolumab is FDA-labeled for adults with moderate-to-severe SLE receiving standard therapy, but its label does not recommend it for severe active kidney or central-nervous-system lupus and highlights infection risks.", "relatedClaimIds": [ "ifn-blockade-mixed-phase3", "care-organ-context" ], "reviewState": "citation-audited", "studyDesigns": [ "guideline-or-regulatory", "randomized-controlled-trial" ], "technicalText": "The April 2026 U.S. label indicates anifrolumab for adults with moderate-to-severe SLE receiving standard therapy. It states that efficacy has not been evaluated in severe active lupus nephritis or severe active CNS lupus and warns about serious infections, including increased respiratory infection and herpes-zoster risk.", "title": "The U.S. anifrolumab indication and safety warnings have explicit boundaries" }, { "directness": "validated-surrogate", "evidence": [ { "note": "Observed responses in the IFN-low stratum contradict a simple claim that only IFN-high participants can respond, although the low subgroup was small.", "relation": "contradicts", "sourceId": "morand-2020-tulip-2" }, { "note": "The IFN-high subgroup did not meet the prespecified SRI-4 secondary endpoint in TULIP-1.", "relation": "qualifies", "sourceId": "furie-2019-tulip-1" }, { "note": "The discovery study established association, not prospective treatment-selection performance.", "relation": "qualifies", "sourceId": "baechler-2003-ifn-signature" } ], "evidenceStatus": "emerging-preliminary", "exportReviewState": "citation-audited", "hub": "interferon", "id": "ifn-signature-not-binary-selector", "lastVerified": "2026-07-10", "limitations": [ "The IFN-low trial subgroup was small and confidence intervals are consequently wide", "A continuous, dynamic, tissue-specific, or multi-marker assay could perform differently from a binary blood signature", "This is a boundary on biomarker interpretation, not evidence that interferon state is clinically irrelevant" ], "plainLanguage": "A high interferon signature may describe biology, but current trial data do not justify using a simple high-versus-low result to guarantee or rule out response to interferon blockade.", "relatedClaimIds": [ "ifn-blood-signature-subgroup", "ifn-blockade-mixed-phase3" ], "reviewState": "citation-audited", "studyDesigns": [ "randomized-controlled-trial" ], "technicalText": "TULIP-2 reported anifrolumab-placebo BICLA differences in both IFN-high and the much smaller IFN-low strata, while TULIP-1 did not show a significant SRI-4 difference in its IFN-high subgroup. These results do not validate baseline binary IFN-gene-signature status as a stand-alone predictive biomarker.", "title": "Baseline interferon-signature status is not a validated binary treatment-selection rule" }, { "directness": "inference", "evidence": [ { "note": "FMT pilot did not involve CAR-T.", "relation": "qualifies", "sourceId": "huang-2022-explorer-fmt" }, { "note": "CAR-T case series did not include microbiome intervention.", "relation": "qualifies", "sourceId": "muller-2024-car-t-autoimmune" } ], "evidenceStatus": "site-hypothesis", "exportReviewState": "citation-audited", "hub": "microbiome", "id": "microbiome-adjunct-unproven", "lastVerified": "2026-07-10", "limitations": [ "Potential infection risk may be especially relevant after lymphodepletion", "Specific probiotic organisms should not be represented as a protocol without clinical evidence" ], "plainLanguage": "No cited study shows that FMT, probiotics, or a selected bacterial mix makes CAR-T safer or more durable in lupus.", "relatedClaimIds": [ "microbiome-fmt-pilot", "cart-reconstitution-naive-b-cells" ], "reviewState": "citation-audited", "studyDesigns": [ "case-series", "nonrandomized-interventional", "animal-model" ], "technicalText": "Combining microbiome manipulation with B-cell reconstitution after CAR-T is a mechanistic hypothesis. The source set contains neither a post-CAR-T intervention study nor validated organisms, doses, timing, or safety criteria for such a combination.", "title": "Microbiome treatment after CAR-T is an untested combination" }, { "directness": "human-mechanism", "evidence": [ { "note": "Pooled 11 case-control studies and reported lower diversity/richness measures in SLE.", "relation": "supports", "sourceId": "xiang-2022-microbiome-meta" } ], "evidenceStatus": "observational-association", "exportReviewState": "citation-audited", "hub": "microbiome", "id": "microbiome-dysbiosis-association", "lastVerified": "2026-07-10", "limitations": [ "Geography, diet, sequencing pipeline, medication, and disease activity can affect results", "Associations do not distinguish cause from consequence", "Individual taxa findings are not fully consistent across studies" ], "plainLanguage": "Across several studies, people with lupus had differences in gut microbial diversity and some bacterial groups compared with healthy controls. Medicines and active disease can also change the microbiome, so the direction of cause is unclear.", "relatedClaimIds": [ "microbiome-r-gnavus-nephritis", "microbiome-fmt-pilot", "microbiome-not-required" ], "reviewState": "citation-audited", "studyDesigns": [ "systematic-review", "case-control" ], "technicalText": "A meta-analysis of 11 case-control studies found lower Shannon diversity and Chao1 richness in SLE. Taxonomic signals were less uniform, and treatment exposure is an important confounder.", "title": "SLE is associated with altered gut microbial diversity and composition" }, { "directness": "clinical-outcome", "evidence": [ { "note": "Primary single-arm pilot and source of the 42.12% week-12 SRI-4 figure.", "relation": "supports", "sourceId": "huang-2022-explorer-fmt" }, { "note": "Defines the SRI composite and why it is not remission.", "relation": "defines", "sourceId": "furie-2009-sri" } ], "evidenceStatus": "emerging-preliminary", "exportReviewState": "citation-audited", "hub": "microbiome", "id": "microbiome-fmt-pilot", "lastVerified": "2026-07-10", "limitations": [ "No placebo or concurrent control", "Only 20 participants and 12 weeks", "Participants continued stable background treatment", "The article has an erratum; exact reuse should be checked against the corrected record", "FMT has infection and transmission risks and is not established SLE care" ], "plainLanguage": "In a 20-person pilot, 42.12% met a trial response measure after oral donor-microbiota capsules plus their usual stable treatment. Without a control group, we cannot know how much of that change came from FMT.", "relatedClaimIds": [ "microbiome-dysbiosis-association", "microbiome-adjunct-unproven" ], "reviewState": "citation-audited", "studyDesigns": [ "nonrandomized-interventional" ], "technicalText": "The EXPLORER single-arm pilot administered encapsulated FMT weekly for three weeks to 20 people with active SLE. At week 12, 42.12% met SRI-4, with changes in disease activity, anti-dsDNA, microbial composition, metabolites, and immune measures. It was a feasibility signal, not a comparative efficacy estimate.", "title": "A small uncontrolled FMT pilot reported SRI-4 responses" }, { "directness": "inference", "evidence": [ { "note": "Human studies establish association and identify medication effects, not necessity.", "relation": "qualifies", "sourceId": "xiang-2022-microbiome-meta" }, { "note": "Preclinical transfer shows modification of immune features, not a universal human initiating mechanism.", "relation": "qualifies", "sourceId": "ma-2019-mouse-fmt" } ], "evidenceStatus": "contradicted", "exportReviewState": "citation-audited", "hub": "microbiome", "id": "microbiome-not-required", "lastVerified": "2026-07-10", "limitations": [ "This conclusion does not exclude important causal effects for particular microbes or patient subgroups" ], "plainLanguage": "The microbiome may influence disease activity, but the evidence does not support calling it the single cause or an essential driver in every person with lupus.", "relatedClaimIds": [ "microbiome-dysbiosis-association", "microbiome-preclinical-transfer" ], "reviewState": "citation-audited", "studyDesigns": [ "systematic-review", "animal-model" ], "technicalText": "Human evidence is predominantly observational, while transfer evidence is preclinical. Together these support a modifier or contributor model more strongly than a universal initiating mechanism.", "title": "Current evidence does not show that a specific microbiome is required to initiate SLE" }, { "directness": "model-organism", "evidence": [ { "note": "Primary germ-free mouse transfer experiment.", "relation": "supports", "sourceId": "ma-2019-mouse-fmt" } ], "evidenceStatus": "preclinical-evidence", "exportReviewState": "citation-audited", "hub": "microbiome", "id": "microbiome-preclinical-transfer", "lastVerified": "2026-07-10", "limitations": [ "Mouse transfer experiments do not establish causality or therapeutic benefit in human SLE", "Results depend strongly on host genetics, housing, diet, and donor community" ], "plainLanguage": "Moving gut microbes from lupus-prone mice into germ-free mice increased some lupus-related immune signals. That supports biological plausibility but does not tell us whether a microbiome treatment helps people.", "relatedClaimIds": [ "microbiome-dysbiosis-association", "microbiome-not-required" ], "reviewState": "citation-audited", "studyDesigns": [ "animal-model" ], "technicalText": "A preclinical FMT experiment reported that microbiota from lupus-prone mice increased anti-dsDNA antibodies and altered immune-cell and gene-expression measures in germ-free recipients.", "title": "Microbiota transfer can modify lupus-like immune features in mice" }, { "directness": "human-mechanism", "evidence": [ { "note": "Primary human observational study with validation across cohorts.", "relation": "supports", "sourceId": "azzouz-2019-r-gnavus" } ], "evidenceStatus": "observational-association", "exportReviewState": "citation-audited", "hub": "microbiome", "id": "microbiome-r-gnavus-nephritis", "lastVerified": "2026-07-10", "limitations": [ "The antibody response was not uniform across R. gnavus strains", "Temporal direction and causal effect are unresolved", "Do not translate this association into antimicrobial or probiotic self-treatment advice" ], "plainLanguage": "One human study found more R. gnavus in lupus and stronger antibody responses to particular strains in people with active kidney disease. This is a lead to investigate, not proof that the bacterium caused nephritis.", "relatedClaimIds": [ "microbiome-dysbiosis-association", "microbiome-fmt-pilot" ], "reviewState": "citation-audited", "studyDesigns": [ "case-control" ], "technicalText": "Azzouz et al. reported approximately fivefold greater overall R. gnavus representation in SLE and associations among strain-restricted anti-R. gnavus lipoglycan antibodies, disease activity, anti-native DNA, complement, and active nephritis.", "title": "Ruminococcus gnavus expansion and strain-specific immunity correlate with active lupus nephritis" } ] }